Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
Company Information
About this company
Key people
William K. McVicar
Independent Chairman of the Board
Frederick E. Pierce
Chief Executive Officer, Director
Mark J. Rosenblum
Chief Financial Officer, Executive Vice President
Barbara Hibner
Chief Scientific Officer
Peter Marschel
Chief Business Officer
David J. Arthur
Director
Tess Burleson
Independent Director
Arnold C. Hanish
Independent Director
Paul I. Lammers
Independent Director
Click to see more
Key facts
- Shares in issue531,968.00
- EPICDCOY
- ISINUS79400X6022
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$3.23m
- Employees11
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.